Patents by Inventor Stefan H. I. Kappe

Stefan H. I. Kappe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Doubly attenuated late liver stage malaria parasites and related compositions and methods
    Patent number: 11529404
    Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: December 20, 2022
    Assignee: SEATTLE CHILDREN'S HOSPITAL
    Inventors: Ashley M. Vaughan, Stefan H. I. Kappe, Dorender A. Dankwa
  • Doubly attenuated late liver stage malaria parasites and related compositions and methods
    Patent number: 10905753
    Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP 2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: February 2, 2021
    Inventors: Ashley M. Vaughan, Stefan H. I. Kappe, Dorender A. Dankwa
  • liver stage antigens
    Patent number: 8318183
    Abstract: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: November 27, 2012
    Assignees: Seattle Biomedical Research Institute, The United States of America, as Represented by the Secretary of the Army, on Behalf of the Walter Reed Army Institute of Research, Philadelphia Health & Education Corporation
    Inventors: Patrick Duffy, Stefan H. I. Kappe, Urszula Krzych, Donald G. Heppner, Lawrence W. Bergman, Vladislav A. Malkov, Alice Tarun, Jason P. Wendler, Igor Bacik
  • Live genetically attenuated malaria vaccine
    Patent number: 8168166
    Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: May 1, 2012
    Assignees: Seattle Biomedical Research Institute, Walter and Eliza Hall Institute of Medical Research
    Inventors: Stefan H. I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller, Kelley van Buskirk, Mehdi Labaied, Ahmed Sayed Ibrahim Aly, Alan Frederick Cowman, Alexander Gerd Maier
  • PLASMODIUM AXENIC LIVER STAGES AS A NONINFECTIOUS WHOLE ORGANISM MALARIA VACCINE
    Publication number: 20100210004
    Abstract: The present invention relates to the treatment and prevention of malaria infection. In particular, the present invention provides novel noninfectious, whole organism vaccines for malaria, which vaccines comprise a Plasmodium axenic liver stage. The invention also provides methods to treat and prevent malaria by administering such Plasmodium axenic liver stage vaccines, as well as methods to generate Plasmodium axenic liver stages.
    Type: Application
    Filed: January 8, 2010
    Publication date: August 19, 2010
    Applicant: NEW YORK UNIVERSITY
    Inventors: Stefan H. I. Kappe, Victor Nussenzweig, Karine Kaiser, Nelly Camargo, Agam P. Singh
  • Live genetically engineered protozoan vaccine
    Patent number: 7722860
    Abstract: The invention provides methods for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host. Representative protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida. The vertebrate host may be a mammal or a bird.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: May 25, 2010
    Assignee: Seattle Biomedical Research Institute
    Inventors: Stefan H. I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller
  • Live genetically attenuated malaria vaccine
    Patent number: 7718165
    Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: May 18, 2010
    Assignees: Seattle Biomedical Research Institute, Ruprecht-Karls-Universitat Heidelberg
    Inventors: Stefan H. I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller
  • PLASMODIUM LIVER STAGE ANTIGENS
    Publication number: 20090017055
    Abstract: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.
    Type: Application
    Filed: September 29, 2006
    Publication date: January 15, 2009
    Applicants: SEATTLE BIOMEDICAL RESEARCH INSTITUTE, REED ARMY INSTITUTE OF RESEARCH, PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A/ DREXEL UNIVERSITY COLLEGE OF MEDICINE DUCOM
    Inventors: Patrick Duffy, Stefan H. I. Kappe, Urszula Krzych, Donald G. Heppner, JR., Lawrence W. Bergman, Vladislav A. Malkov, Alice Tarun, Jason W. Wendler, Igor Bacik
  • Live genetically attenuated malaria vaccine
    Patent number: 7261884
    Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: August 28, 2007
    Assignees: Seattle Biomedical Research Institute, Ruprecht-Karls-Universitat Heidelberg
    Inventors: Stefan H. I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller
  • Live genetically attenuated malaria vaccine
    Patent number: 7122179
    Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a gene whose expression is up-regulated in liver stage parasites and whose function is not required for entry into hose hepatocytes.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: October 17, 2006
    Assignees: Seattle Biomedical Research Institute, Ruprecht-Karls-Universität Heidelberg
    Inventors: Stefan H. I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller